Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tagliabue, Elda"'
Autor:
Tiwari S; Departments of Medicine and Pharmacology, University of California San Diego, La Jolla, CA, USA., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Holton S; University of Washington, Seattle, WA, USA., Regondi V; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Paolini B; Anatomic Pathology A Unit, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bhargava R; Departments of Bioengineering, Electrical and Computer Engineering, Mechanical Science and Engineering, Chemical and Biomolecular Engineering and Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL, USA. rxb@illinois.edu.; Cancer Center at Illinois and Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, USA. rxb@illinois.edu.
Publikováno v:
Scientific reports [Sci Rep] 2020 Mar 25; Vol. 10 (1), pp. 5442. Date of Electronic Publication: 2020 Mar 25.
Autor:
Di Cosimo S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Triulzi T; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Pizzamiglio S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., De Cecco L; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., de Azambuja E; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., Fumagalli D; Breast International Group (BIG)-aisbl, Bruxelles, Belgium., Putzai L; Yale Cancer Center, Yale School of Medicine, New Haven, USA., Harbeck N; Brustzentrum der Universität München (LMU), Munchen, Germany., Izquierdo M; Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland., Peña L; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Daidone MG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Huober J; University of Ulm, Ulm, Germany., Gori S; IRCCS Sacro Cuore-Don Calabria Hospital, Negrar, Verona, Italy., Cinieri S; Antonio Perrino Hospital, Brindisi, Italy., Torri V; IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri' Milano, Italy., Baselga J; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Piccart M; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., de Braud FG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Apolone G; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Verderio P; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Tagliabue E; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: elda.tagliabue@istitutotumori.mi.it.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Sep; Vol. 118, pp. 1-9. Date of Electronic Publication: 2019 Jul 05.
Autor:
Triulzi T; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Cecco L; Department of Experimental Oncology and Molecular Medicine, Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sandri M; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Prat A; Translational Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.; Medical Oncology Department, Hospital Clínic i Provincial, Barcelona, Spain., Giussani M; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Paolini B; Department of Pathology, Anatomic Pathology A Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Carcangiu ML; Department of Pathology, Anatomic Pathology A Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Canevari S; Department of Experimental Oncology and Molecular Medicine, Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bottini A; Dipartimento di Terapia Molecolare e Farmacogenomica, Istituti Ospitalieri di Cremona, Italy., Balsari A; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Italy., Menard S; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Generali D; Dipartimento di Terapia Molecolare e Farmacogenomica, Istituti Ospitalieri di Cremona, Italy., Campiglio M; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Cosimo S; Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Department of Experimental Oncology and Molecular Medicine, Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2015 Sep 29; Vol. 6 (29), pp. 28173-82.
Autor:
Triulzi T; Authors' Affiliation: Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Orlandi R, Tagliabue E
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2014 Mar 01; Vol. 20 (5), pp. 1396.
Autor:
Indino, Serena, Borzi, Cristina, Moscheni, Claudia, Sartori, Patrizia, De Cecco, Loris, Bernardo, Giancarla, Le Noci, Valentino, Arnaboldi, Francesca, Triulzi, Tiziana, Sozzi, Gabriella, Tagliabue, Elda, Sfondrini, Lucia, Gagliano, Nicoletta, Moro, Massimo, Sommariva, Michele
Publikováno v:
International Journal of Molecular Sciences; Dec2022, Vol. 23 Issue 24, p15802, 22p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Romero-Cordoba, Sandra, Meneghini, Elisabetta, Sant, Milena, Iorio, Marilena Valeria, Sfondrini, Lucia, Paolini, Biagio, Agresti, Roberto, Tagliabue, Elda, Bianchi, Francesca
Publikováno v:
Cancers; Jul2019, Vol. 11 Issue 7, p911-911, 1p
Autor:
Silvana Canevari, Andrea Balsari, Sylvie Ménard, Serena Di Cosimo, Marta Giussani, Aleix Prat, Marialuisa L. Carcangiu, Manuela Campiglio, Daniele Generali, Biagio Paolini, Elda Tagliabue, Loris De Cecco, Alberto Bottini, Tiziana Triulzi, Marco Sandri
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinom